Elias Kouchakji's Insider Trades & SAST Disclosures
Elias Kouchakji's most recent trade in FibroGen Inc was a trade of 5,221 Common Stock done at an average price of $33.4 . Disclosure was reported to the exchange on March 8, 2021.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Elias Kouchakji.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| FibroGen Inc | Elias Kouchakji | SVP, Clinical Dev, Drug Safety | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.37 per share. | 08 Mar 2021 | 5,221 | 147,346 (0%) | 0% | 33.4 | 174,225 | Common Stock |
| FibroGen Inc | Elias Kouchakji | SVP, Clinical Dev, Drug Safety | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 39,900 | 39,900 | - | - | Stock Option (Right to Buy) | |
| FibroGen Inc | Elias Kouchakji | SVP, Clinical Dev, Drug Safety | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 20,800 | 152,567 (0%) | 0% | 0 | Common Stock | |
| FibroGen Inc | Elias Kouchakji | SVP, Clinical Dev, Drug Safety | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.99 per share. | 07 Dec 2020 | 2,728 | 131,767 (0%) | 0% | 42.0 | 114,549 | Common Stock |
| FibroGen Inc | Elias Kouchakji | SVP, Clinical Dev, Drug Safety | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2020 | 7,082 | 0 | - | - | Stock Option (Right to Buy) | |
| FibroGen Inc | Elias Kouchakji | SVP, Clinical Dev, Drug Safety | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.57 per share. | 17 Nov 2020 | 7,082 | 134,495 (0%) | 0% | 14.6 | 103,220 | Common Stock |
| FibroGen Inc | Elias Kouchakji | SVP, Clinical Dev, Drug Safety | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.16 per share. | 08 Sep 2020 | 2,728 | 127,413 (0%) | 0% | 42.2 | 115,012 | Common Stock |
| FibroGen Inc | Elias Kouchakji | SVP, Clinical Dev, Drug Safety | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.61 per share. | 08 Jun 2020 | 2,728 | 130,141 (0%) | 0% | 33.6 | 91,688 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges